Wegovy's market share in the UK: what the numbers actually tell you

Step 1, First to market and what that advantage meant

Wegovy arrived in UK pharmacies in late 2023, having received its NICE recommendation in March of that year. Being first in a new medicine category matters. Clinicians built familiarity with the subcutaneous pen, patient support programmes were established around it, and NHS specialist weight management services calibrated their pathways to it. That institutional familiarity is a durable form of market share, separate from any price or efficacy comparison.

The early supply was constrained (a shortage that ran through much of 2023 and into 2024) which paradoxically kept patient numbers lower than demand warranted. When supply stabilised, pent-up demand accelerated uptake quickly. By the time Wegovy formally reached the market in volume, it was already the reference point against which every other option would be measured. Novo Nordisk's investment in patient awareness and its relationship with NHS England gave semaglutide a profile that newer entrants had to work against, not ignore.

On the private side, clinics and online pharmacies including services offering Wegovy built their initial prescription volumes around semaglutide precisely because it was available first. That structural head-start translates into cumulative prescribing data, real-world safety signals and growing clinician confidence, all of which reinforce a product's position.

Step 2, Tirzepatide enters and the competitive map shifts

Mounjaro (tirzepatide) received its UK licence for weight management in November 2023 and NICE issued its positive appraisal (TA1026) in December 2024. As a dual GIP and GLP-1 receptor agonist (the only medicine of its kind licensed for weight loss in the UK) tirzepatide offered a mechanistically distinct option, not simply a rival dose of the same drug. Trial results from SURMOUNT-1 showed average body-weight reductions of around 20–21% at the highest dose over 72 weeks, and the subsequent SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine, confirmed greater average weight loss with tirzepatide than with semaglutide 2.4mg in adults with obesity and no diabetes.

That evidence shifted prescriber conversations. Clinicians who had been prescribing Wegovy as a default began weighing whether tirzepatide's efficacy profile suited particular patients better, especially those who had not reached their goals at semaglutide's 2.4mg maintenance dose. The commercial picture for Wegovy's market position became more competitive as a result, though semaglutide retained advantages in familiarity, its established NHS pathway and a longer post-marketing safety record.

Wegovy's response, in clinical terms, was the 7.2mg approval. Trials reported roughly 20.7% average weight loss over 72 weeks at that dose, narrowing the gap with tirzepatide's headline figures. The dedicated single-dose 7.2mg pen, approved by the MHRA on 14 April 2026, simplified administration and opened a new chapter for the product's trajectory.

Step 3, New indications and why they broaden Wegovy's reach

A medicine's market position is not static. Wegovy now holds UK approvals beyond weight management: a licence for reducing the risk of major cardiovascular events in eligible adults, and (from 3 July 2026) a conditional approval for MASH (metabolic dysfunction-associated steatohepatitis), a form of progressive fatty liver disease, in adults with moderate-to-advanced fibrosis. The MHRA's announcement of the MASH approval is confirmed on GOV.UK.

These additional indications matter for market share because they expand the eligible patient population beyond people seeking weight loss. Cardiologists, hepatologists and GPs managing metabolic syndrome now have a regulatory basis to consider semaglutide that sits outside the weight management pathway entirely. For Novo Nordisk's broader strategy, this positions Wegovy as a metabolic medicine rather than a weight-loss-only product, a distinction that matters both clinically and commercially.

Oral semaglutide (Wegovy tablets) added a further dimension when the MHRA approved it on 11 June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management. The tablet's convenience (room-temperature storage, no injections, straightforward to keep in a handbag or gym bag) is expected to attract patients who have hesitated at the prospect of weekly injections. Whether that broadens Wegovy's overall reach or simply shifts existing demand from pen to tablet remains to be seen, but it gives semaglutide a product format that tirzepatide currently cannot match.

Step 4, What this means if you are weighing up treatment options

Market share figures are useful context but they are not a clinical guide. The question is not which medicine is more popular; it is which is appropriate for you. Both Wegovy and Mounjaro are licensed for weight management in the UK, both are prescription-only, and both require clinical assessment before a prescription is issued. Semaglutide's profile suits many patients well; others, for clinical reasons, are better candidates for tirzepatide. A good prescriber discusses the evidence, your medical history and your preferences before making that call. You can read a broader overview of how Wegovy works and who it is licensed for if that context helps before a consultation.

On the supply side, the grey market in semaglutide has complicated the picture throughout this period. Counterfeit and unlicensed products circulate online, and the MHRA has issued repeated warnings about fake pens found to contain incorrect or unlabelled substances. Any medicine sourced outside a GPhC-registered pharmacy, without a proper prescription, carries risks that no saving justifies. Checking a pharmacy's registration on the GPhC register before ordering is a straightforward step that takes under a minute.

If you would like to discuss which licensed treatment suits your circumstances, speak to our prescribers through a free consultation reviewed the same day by a GPhC-registered Independent Prescriber. There is no obligation and no subscription.